Maridith Hollis, MD
Psychiatry · Daphne, ALNPI 1730612086
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,830 of the $17,121 with a category attached, or 63.3%. Alkermes, Inc. accounts for 82.5% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $14,726, more than ten times the $96 reported in 2019. Among psychiatry clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 130 payments — averaging $131.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$14K
- E.r. Squibb & Sons, L.L.C.$519
- Otsuka America Pharmaceutical, Inc.$399
- Indivior Inc.$325
- Teva Pharmaceuticals USA, Inc.$320
- AbbVie$303
- plus $1K from 10 others
What the payments were for
- Consulting fees$1,6009%
- Speaking & faculty fees$10,83063%
- Travel & lodging$5463%
- Food & beverage$3,98923%
- Education$1561%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 38 | $14,130 |
| E.r. Squibb & Sons, L.L.C. | 16 | $519 |
| Otsuka America Pharmaceutical, Inc. | 12 | $399 |
| Indivior Inc. | 10 | $325 |
| Teva Pharmaceuticals USA, Inc. | 13 | $320 |
| AbbVie(2 entities) | 6 | $303 |
| Neurocrine Biosciences, Inc. | 10 | $234 |
| Vanda Pharmaceuticals Inc. | 5 | $230 |
| Johnson & Johnson | 5 | $187 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $173 |
| Dendreon Pharmaceuticals LLC | 1 | $150 |
| Lundbeck LLC | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $41 |
| Shire North American Group Inc | 2 | $26 |
| Braeburn Inc. | 1 | $23 |
| Adlon Therapeutics L.p. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$51,904
- ARISTADA$910
- VRAYLAR$250
- COBENFY$224
- PROVENGE$150
- ARISTADA INITIO$125
- Fanapt$125
- ABILIFY ASIMTUFII$125
- ABILIFY MAINTENA$125
- CAPLYTA$123
- SUBLOCADE$122
- SPRAVATO$109
How this compares
$17,121 in reported general payments places this provider in the 90th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Divalproex Sodium ErDivalproex Sodium | 12 | $288 |
| Benztropine Mesylate | 13 | $136 |
| Trazodone Hcl | 19 | $93 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Daphne
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
- Scariya KumaramangalamHuntsville$440K
- Mark HaygoodMobile$348K
- Lori DavisTuscaloosa$161K
- Bradley SadlerMobile$124K
- Brandi Rudolph BollingJasper$97K
- Richard SheltonBirmingham$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.